1353151-22-0 ((Nilotinib)

4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide;NILOTINIB [INN];Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- (9CI);BCP01367;UNII-F41401512X;Nilotinib (AMN-107);SW218083-2;HMS3244A14;SR-01000931150-2;Benzamide, 4-methyl-N-((3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-;CCG-264784;N-(3-(3-(1H-Imidazolyl)propoxy)phenyl)-4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)benzamide;benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-;AMN-107;D08953;Nilotinib free base;Benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-;NILOTINIB [USP-RS];Nilotinib?;CHEBI:52172;SCHEMBL29580067;AKOS005063561;MLS006010160;AB01273978-01;AMN 107;HMS5079M05;Nilotinib,AMN107,Tasigna;4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;NILOTINIB [MI];Nilotinib (USAN/INN);4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide;CS-0102;EX-A8380;NCGC00183285-03;SB17315;L01XE08;4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide;F41401512X;4-Methyl-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide;4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino] benzamide;MSK159953;4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide;SR-01000931150;Danziten;4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;HY-10159R;Z1741976994;NSC-747599;4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide;4-Methyl-N-[3-(4-methyl-1-imidazolyl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridyl)-2-pyrimidyl]amino]benzamide;HMS3654M07;TAC35617;s1033;NCGC00183285-09;GTPL5697;HMS3295A23;Nilotinib;NILOTINIB [EMA EPAR];4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzamide;HY-10159;NSC800804;AS-16214;HMS3244A13;NCGC00183285-04;SMR002544680;NSC-800804;SY024415;AC-647;EC 700-544-5;4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide;Nilotinib (Standard);4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-{(4-(pyridin-3-yl)pyrimidin-2-yl)amino}benzamide;AMN107;Nilotinib [USAN:INN:BAN];AB01273978-02;BN164654;Nilotinib - Bio-X trade mark;4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide;4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)-phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide;AMN 107 Base;NILOTINIB [VANDF];HMS3244B13;4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide;MFCD09833716;NSC747599;1353151-22-0;BDBM50237710;NCGC00183285-15;RefChem:58968;DTXCID3022663;4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide;4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]benzamide;MLS003915611;NSC 747599;N-8207;Q412327;NILOTINIB [HSDB];DTXSID5042663;BCP9000989;NILOTINIB [WHO-DD];DB04868;BRD-K81528515-001-04-7;NCGC00183285-01;AB01273978_03;641571-10-0;NILOTINIB [MART.];Tasigna;FM10831;641571-10-0 (free base);3gp0;EN300-7381984;4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4 -pyridin-3-ylpyrimidin-2-yl)amino]benzamide;BRD-K81528515-001-13-8;C28H22F3N7O;HSDB 7842;SDCCGSBI-0634418.P004;nilotinibum;CHEMBL255863;NS00000665;HMS3748E11;SCHEMBL29366964;BCPP000149;Nilotinib [USAN];benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, hydrochloride, hydrate;orb1308331;SCHEMBL7901;

HHZIURLSWUIHRB-UHFFFAOYSA-N

1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)

FC(C1C=C(C=C(C=1)N1C=NC(C)=C1)NC(C1C=CC(C)=C(C=1)NC1N=CC=C(C2C=NC=CC=2)N=1)=O)(F)F